trending Market Intelligence /marketintelligence/en/news-insights/trending/Sl8jhJKQ3TpujY4vzPk4XA2 content esgSubNav
In This List

Neos Therapeutics settles patent case against Teva unit for ADHD drug

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Neos Therapeutics settles patent case against Teva unit for ADHD drug

Neos Therapeutics Inc. agreed to settle its patent infringement case filed against a unit of Teva Pharmaceutical Industries Ltd.

Neos filed a complaint in December 2017 with the U.S. District Court for the District of Delaware alleging that an abbreviated new drug application for the generic version of Cotempla XR-ODT, or methylphenidate, filed with the U.S. Food and Drug Administration by Teva unit Teva Pharmaceuticals USA Inc. infringed its patents.

Under the agreement, Neos has given Teva rights to manufacture and market the generic version of Cotempla XR-ODT starting in 2026 or earlier under certain circumstances.

Cotempla XR-ODT is approved by the FDA to treat attention deficit hyperactivity disorder in patients aged 6 to 17 years old.

Neos did not share any details of the agreement, which is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.